Impact of Rapid Ventricular Pacing During Transcatheter Implantation of Self-Expanding Aortic Valve Prostheses in Patients at Highest Risk.


Journal

The Journal of invasive cardiology
ISSN: 1557-2501
Titre abrégé: J Invasive Cardiol
Pays: United States
ID NLM: 8917477

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 23 11 2020
medline: 24 8 2021
entrez: 22 11 2020
Statut: ppublish

Résumé

Patients with low-flow, low-gradient (LFLG) aortic stenosis (AS) have the highest risk among all AS patients. Rapid ventricular pacing (RVP) is frequently used during transcatheter aortic valve implantation (TAVI), but may negatively impact critical left ventricular function in these patients. We investigated the effects of RVP in patients with LFLG-AS undergoing implantation of a self-expandable valve prosthesis. In this retrospective study, patients with LFLG-AS were classified according to the number of cumulative RVP episodes. Thirty-one patients with no episodes of RVP, 46 patients with 1 episode, and 40 patients with 2 or more episodes (2+) were identified. Society of Thoracic Surgeons (STS) scores in patients with 0, 1, or 2+ RVP episodes were 5.1% (interquartile range [IQR], 3.5%-8.9%), 6.0% (IQR, 3.8%-8.8%), and 4.8% (3.8%-8.1%), respectively. Peri-interventional adverse events tended to be highest in the group with 1 RVP. Residual aortic regurgitation was in 3.2%, 4.8%, and 2.6% (P=.87) in patients with 0, 1, and 2+ RVP episodes, respectively. Thirty-day mortality rates were 3.2%, 6.5%, and 7.5% (P=.74) and 1-year mortality rates were 22.6%, 30.4%, and 20.0% (P=.51) in patients with 0, 1, and 2+ RVP episodes, respectively. STS score, body mass index, prevalence of chronic lung disease, and more-than-mild residual aortic regurgitation emerged as independent predictors of 1-year mortality, whereas the number of RVP episodes had no impact on outcomes. One-year mortality is not influenced by RVP, but is influenced by the individual patient's risk. The final implantation results in patients with 2+ RVP episodes suggest that RVP during implantation of self-expandable TAVI prostheses should not be withheld in an attempt to achieve optimal results, even in LFLG-AS patients.

Sections du résumé

BACKGROUND BACKGROUND
Patients with low-flow, low-gradient (LFLG) aortic stenosis (AS) have the highest risk among all AS patients. Rapid ventricular pacing (RVP) is frequently used during transcatheter aortic valve implantation (TAVI), but may negatively impact critical left ventricular function in these patients. We investigated the effects of RVP in patients with LFLG-AS undergoing implantation of a self-expandable valve prosthesis.
METHODS METHODS
In this retrospective study, patients with LFLG-AS were classified according to the number of cumulative RVP episodes.
RESULTS RESULTS
Thirty-one patients with no episodes of RVP, 46 patients with 1 episode, and 40 patients with 2 or more episodes (2+) were identified. Society of Thoracic Surgeons (STS) scores in patients with 0, 1, or 2+ RVP episodes were 5.1% (interquartile range [IQR], 3.5%-8.9%), 6.0% (IQR, 3.8%-8.8%), and 4.8% (3.8%-8.1%), respectively. Peri-interventional adverse events tended to be highest in the group with 1 RVP. Residual aortic regurgitation was in 3.2%, 4.8%, and 2.6% (P=.87) in patients with 0, 1, and 2+ RVP episodes, respectively. Thirty-day mortality rates were 3.2%, 6.5%, and 7.5% (P=.74) and 1-year mortality rates were 22.6%, 30.4%, and 20.0% (P=.51) in patients with 0, 1, and 2+ RVP episodes, respectively. STS score, body mass index, prevalence of chronic lung disease, and more-than-mild residual aortic regurgitation emerged as independent predictors of 1-year mortality, whereas the number of RVP episodes had no impact on outcomes.
CONCLUSIONS CONCLUSIONS
One-year mortality is not influenced by RVP, but is influenced by the individual patient's risk. The final implantation results in patients with 2+ RVP episodes suggest that RVP during implantation of self-expandable TAVI prostheses should not be withheld in an attempt to achieve optimal results, even in LFLG-AS patients.

Identifiants

pubmed: 33221732
pii: JIC20201122-2
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E355-E361

Auteurs

Ulrich Fischer-Rasokat (U)

Kerckhoff Heart Center, Benekestr. 2-8, 60231 Bad Nauheim, Germany. u.fischer-rasokat@kerckhoff-klinik.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH